113PANLOTINIB AS THIRD-LINE TREATMENT IN PATIENTS WITH REFRACTORY ADVANCED NON-SMALL CELL LUNG CANCER: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL (NCT01924195)


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles